Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 283-289

  Etienne, M C ^a   Guillot, T ^b   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Laboratoires Wyeth Lederle   (France)

Author keywords

5 fluorouracil; Folinic acid; Pharmacomodulation

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG COMBINATION; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029986838     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010573     Document Type: Review

References (66)

1. Dreyfuss AI, Clark JR, Wright JE et al. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Int Med 1990; 112: 167-72.
2. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890-9.
3. Peters GJ, Van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991; 2: 469-80.
4. Grem JL. Fluorinated pyrimidines. In Chabner BA, Collins JM (eds): Cancer Chemotherapy, Principles and Practise. Philadelphia: Lippincott 1990; 180-225.
5. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HTC-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-64.
6. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 1988; 28: 14402-9.
7. Bertrand R, Jolivet J. Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 1989; 81: 1175-8.
8. Abad A, Garcia P, Gravalos C et al. Sequential methotrexate, 5-fluorouracil (5-FU) and high dose leucovorin versus 5-FU and high-dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer 1995; 75: 1238-44.
9. Doroshow JH, Multhauf P, Leong L et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous-infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491-501.
10. Petrelli N, Herrera L, Rustum Y et al. A prospective randomized trial of 5-ftuorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-65.
11. Erlichman C, Fine S, Wong A, Elhakin T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
12. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
13. Nobile MT, Vidili MG, Sobrero A et al. 5-Fluorouracil alone or combined with high-dose folinic acid in advanced colorectal cancer patients: A randomized trial. Proc ASCO 1988; 7: 371 (Abstr).
14. Petrelli N, Douglas HO, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-25.
15. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal cancer and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685-96.
16. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
17. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
18. Francini G, Petrioli R, Lorenzini L et al. Folinic acid and fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899-906.
19. O'Connell M, Mailliard J, MacDonald J et al. An intergroup trial of intensive course 5-FU and low-dose leucovorin as surgical adjuvant therapy for high-risk colon cancer. Proc ASCO 1993; 12: 552 (Abstr).
20. Pinedo HM, Peters GJ. 5-Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
21. Peters GJ, Laurensse E, Leyra A et al. Sensitivity of human murine and rat cells to 5-fluorouracil and 5-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20-8.
22. Aiba K, Allegra C, Park J, Chabner B. Multifactorial resistance of 5-fluorouracil in human colon cancer cell lines. Proc AACR 1990; 31: 424 (Abstr).
23. Beck A, Etienne MC, Chéradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fruorouracil. Eur J Cancer 1994; 30: 1517-22.
24. Beck A, Etienne MC, Chéradame S et al. Wide range for optimal concentration of folinic acid in fluorouracil modulation - experimental data on human tumor cell lines. Eur J Cancer 1994; 30: 1522-6.
25. Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987; 71: 261-5
26. Peters GJ, Van der Wilt CL, Van Triest B et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31A: 1299-305.
27. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
28. Lenz HJ, Leichman CG, Danenberg KD et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-82.
29. Chazal M, Schneider M, Milano G et al. Clinical resistance to fluorouracil-folinic acid is linked to low folylpolyglutamate synthethase activity in tumors. Proc AACR 1996; in press.
30. Etienne MC, Chéradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
31. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992; 52: 4922-8.
32. Peters GJ, Van der Wilt CL, Van Groeningen CJ et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol 1994; 12: 2035-42.
33. Drake JC, Voeller DM, Allegra CJ, Johnston PG. The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer 1995; 71: 1145-50.
34. Danenberg PV. Thymidylate synthase: A target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977; 473: 73-92.
35. Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthase with lower affinity for nucleotides. J Biol Chem 1983; 258: 4130-6.
36. Barbons KW, Berger SH, Berger FG. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol 1990; 37: 515-8.
37. 44 in a conserved loop guarding the active site has striking effect of catalysis and nucleotide binding. Biochem Biophys Res Commun 1990; 167: 869-75.
38. Hoganson DK, Berger SH. Association between thymidylate synthase structure and colon tumor cell response to biochemical modulation. Proc AACR 1994; 35: 323 (Abstr).
39. Trave F, Rustum YM, Petrelli NJ et al. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 1988; 6: 1184-91.
40. Dohden R, Ohmura K, Watanabe Y. Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. Cancer 1993; 71: 471-80.
41. Kühl M, Jauch K, Engemann B et al. Tissue levels of 5,10 methylenetetrahydrofolate in patients with colorectal carcinoma with or without preoperative treatment with folinic acid or 5 methyltetrahydrofolate. Proc ASCO 1994; 13: 136 (Abstr).
42. Chéradame S, Etienne MC, Fischel JL et al. Are physiological reduced folate concentrations in tumors relevant for optimal FU efficacy? Experimental and clinical answers. Proc AACR 1996; in press.
43. Brown JP, Davidson GE, Scott JM. The identification of the forms of folate found in the liver, kidney and intestine of the monkey and their biosynthesis from pteroylglutamate (folic acid). Biochem Biophys Acta 1974; 343: 78-88.
44. Foo SK, Schane B. Regulation of folylpoly-gamma-glutamate synthesis in mammalian cells. In vitro and in vivo synthesis of pteroylpoly-gamma-glutamates by Chinese hamster ovary cells. J Biol Chem 1982; 257: 13587-92.
45. Lu YZ, Aiello PD. Matthews RG. Studies on the polyglutamate specificity of thymidylate synthase from fetal pig liver. Biochemistry 1984; 23: 6870-6.
46. Radparvar S, Houghton PJ, Houghton JA. Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys 1988; 260: 342-50.
47. Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyltetrahydrofotate in human breast and colon cell lines. Cancer Res 1992; 52: 36-44.
48. Romanini A, Lin JT, Niedzwiecki D et al. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 1991; 51: 789-93.
49. Houghton JA, Williams LG, Loftrin SK et al. Factors that influence the therapeutic activity of 5-fluorouracil - [6RS] leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992; 30: 423-32.
50. Wang FS, Aschele C, Sobrero A et al. Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance. Cancer Res 1993; 53: 3677-80.
51. Leichman LG, Leichman L, Spears CP et al. Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose-seeking clinical trial for patients with disseminated gastrointestinal cancers. Cancer Chemother Pharmacol 1990; 26: 57-61.
52. Poon M, O'Connell M, Wieand H et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
53. Moran RG, Scanlon KL. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991; 51: 4618-23.
54. Zhang ZG, Rustum YM. Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2′-deoxyuridine and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 1991; 51: 3476-81.
55. Newman EM, Straw JA, Doroshow JH. Pharmacokinetics of diastereoisomers of (6 R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 1989; 49: 5755-60.
56. Priest DG, Schmitz JC, Bunni MA, Stuart RK. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 1991; 83: 1806-12.
57. Schneider M, Etienne MC, Milano G et al. Phase II trial of cisplatin, fluorouracil and pure 1 folinic for locally-advanced head and neck cancer: A pharmacokinetic and clinical survey. J Clin Oncol 1995; 13: 1656-62.
58. Vokes EE, Ratain M, Mick R et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 1993; 11: 360-8.
59. Milano G, Etienne MC, Cassuto-Viguier E et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-5.
60. Gamelin E, Maillart P, Dumesnil Y et al. Application of dose intensity to metastatic colorectal cancer. The need for an adaptation of 5-fluorouracil posology. Proc AACR 1992; 33: 1307 (Abstr).
61. Milano G, Etienne MC, Renée N et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12: 1291-5.
62. De Gramont A, Bosset JF, Milan C et al. A prospective randomized trial comparing 5-FU bolus with low-dose folinic acid and 5-FU bolus continuous-infusion with high-dose folinic acid for advanced colorectal cancer. Proc ASCO 1995; 14: 455 (Abstr).
63. Houghton JA, Williams LG, De Graaf SN et al. Relationship between dose rate of 6RS Leucovorin administration, plasma concentrations of reduced folates and pool of 5,10-methylene-tetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990; 50: 3493-502.
64. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous-infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
65. Kish J, Drelichman A, Al Sarraf M et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of head and neck. Cancer Treat Rep 1982; 66: 471-4.
66. Lévi F, Zidani R, Vannetzel JM et al. Chronomodulated versus flat infusion of 5-fluorouracil, folinic acid and oxaliplatin against metastatic colorectal cancer in 2 consecutive European randomized multicenter trials. Proc ASCO 1995; 14: 493 (Abstr).